Takeo Kosaka

42PUBLICATIONS
115CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Neurology and neuromuscular diseasesGender historyEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Jul 10, 2026
Real-World Use of Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma in Japan: Treatment Patterns, Effectiveness, and Safety.

|Jun 03, 2026
Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real-World Multicenter Study.

|May 16, 2026
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

|May 02, 2026
Editorial Comment to "Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First-Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real-World Study (YUSHIMA Study)".

|Apr 07, 2026
Real-World Outcomes After Radical Cystectomy for Muscle-Invasive Bladder Cancer in Japan: A Nationwide Descriptive Study From the National Clinical Database.

Shingo Hatakeyama, Kyoko Yamamoto, Hiroyuki Yamamoto

|Jan 21, 2026
Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma.

Eiji Kikuchi, Michiel S Van der Heijden, Begoña P Valderrama

Pageof 7

Frequent Collaborators

5 joint publications

Nozomi Hayakawa

5 joint publications

Takashi Kobayashi

4 joint publications

Yoshikazu Sato

4 joint publications

Akira Tsujimura